AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Mass Spectrometry-Resolved Apolipoprotein(a) Isoform Phenotyping in ODYSSEY OUTCOMES Reveals Determinants of Apolipoprotein(a) Recovery Beyond KIV-2 Variation
By Diederiks NM, Ruhaak LR, Romijn F et al.
Background: Lipoprotein(a) [Lp(a)] is an independent CVD risk factor and guidelines recommend measuring Lp(a) once in a lifetime. If traceability is correctly implemented, Lp(a) should no longer be the most misunderstood metric in laboratory medicine. Commercial Lp(a) test kits can be made traceable to a higher order standard based on bottom-up proteomics with Mass Spectrometry (MS). The MS-based assay detects peptides outside KIV-2 and enables apo(a) reporting in molar units. Notwithstanding clinical equivalence between immunoassay (IA)- and MS-based apo(a) results, discordances occur. In ODYSSEY OUTCOMES trial (OOT), IA-MS discordances were investigated, focusing on average KIV-2 repeats. Objective: An international IFCC working group on Apolipoprotein Standardization developed a higher order MS-based measurement procedure, independent of apo(a) KIV-2 size polymorphism and traceable to WHO-IFCC SRM2B. The relation between average apo(a) KIV-2 repeats and apo(a) levels was investigated in the OOT with the Roche IA-based 2 nd generation test and the MS-based test. Methods: Beyond total apo(a) levels, the MS-based test quantifies KIV-2 dependent peptides and was explored as alternative for apo(a) phenotyping with Western blotting. KIV-2 repeats were calculated by subtracting nine non-KIV-2 repeats from Western blot derived total KIV number. The MS-based method used GTYST/LFLEP molar ratio minus 3; GTYST reflects KIV-2 dependent number and LFLEP the KIV-2 independent number. In 82 sera, Western blot-derived KIV-2 numbers were compared to MS-based KIV-2 number. The impact of apo(a) size polymorphism on apo(a) test recovery was investigated in the OOT biomarker substudy (N = 10,187, KIV-2 range 3.0-46.6) measured by Roche IA and MS. Results: Western blot-derived dominant KIV-2 number correlates with MS-derived average KIV-2 number spanning 6-29 KIV-2 repeats (Y=3.48 + 0.671X; 95% CI: 0.57-0.77; R = 0.824). Roche IA and MS-results were clinically equivalent in most specimens: (Y=1.6+1.033x, 95% CI: 1.028-1.038; R = 0.969). Notably, 2.5% (N = 255) of the discordant specimens showed systematic underestimation of IA-results compared to MS-results . Discordances were found within lower molecular weight apo(a) KIV-2 isoforms (KIV-2 ≤13), with apo(a) concentrations varying from the LOQ to ~800 nmol/L. Conclusion: We developed and validated a metrologically higher order apo(a) MS-based test for determining apo(a) size polymorphism by calculating selective peptide molar ratios reflecting KIV-2 dependent and independent levels. The IA-MS method comparison in the OOT shows excellent clinical equivalence of molar apo(a) test results in 97.5% of serum specimens. Yet, discordance analysis using MS-resolved apo(a) isoform phenotyping reveals other determinants of apo(a) recovery beyond KIV-2 Copy Number Variation.